

國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(於中華人民共和國註冊成立之股份有限公司,在香港以國控股份有限公司之名稱經營業務)

(Stock Code 股份代號:01099)

NOTIFICATION LETTER 通知信函

30 August 2023

Dear Shareholder (Note 1),

SINOPHARM GROUP CO. LTD.* (the "Company")

NOTICE OF PUBLICATION OF CIRCULAR, NOTICE AND FORM OF PROXY OF EXTRAORDINARY GENERAL MEETING DATED 30 AUGUST 2023 (the "Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at sinopharm.todayir.com and the HKEXnews's website at www.hkexnews.hk. You may access the Current Corporate Communication on the Company's website, or browsing through the HKEXnews's website.

You may at any time choose to receive free of charge the Company's Corporate Communications (Note 2) either in printed form in both Chinese and English versions or in Chinese version only or in English version only, or read the website version, notwithstanding any wish to the contrary you have previously conveyed to the Company. If you wish to receive printed version of the Current Corporate Communication, please complete the Request Form on the reverse side and send it to the Company c/o Computershare Hong Kong Investor Services Limited (the "H Share Registrar"), using the pre-paid mailing label at the bottom of the Request Form (if you post in Hong Kong). Otherwise, please affix an appropriate stamp. The address of the H Share Registrar is 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong. The Request Form may also be downloaded from the Company's website at sinopharm.todayir.com or the HKEXnews's website at www.hkexnews.hk.

If you would like to change your choice of language or means of receipt of the Company's Corporate Communications in the future, please write or send an email to the Company c/o the H Share Registrar at sinopharm.ecom@computershare.com.hk. Even if you have chosen (or are deemed to have consented) to receive the website version of all future Corporate Communications but for any reason you have difficulty in receiving or gaining access to the website version of the Current Corporate Communication, the Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

Should you have any queries relating to any of the above matters, please call the Company's enquiry hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays.

Yours faithfully,
For and on behalf of
Sinopharm Group Co. Ltd.*
Yu Qingming
Chairman

- * The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.
- Note 1: This letter is being sent to the registered holders of the H shares of the Company, whose names appear on the H share register of members of the Company. If you have sold or transferred all your H shares in the Company, please disregard this letter and the Request Form on its reverse side
- Note 2: Corporate Communication (the "Corporate Communication") of the Company refers to any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the annual report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位股東(附註1):

國藥控股股份有限公司(「本公司」)

- 日期為二零二三年八月三十日之股東特別大會之通函、通告及代表委任表格(「本次公司通讯」)之發佈通知

本公司的本次公司通訊中、英文版本已上載於本公司網站 <u>sinopharm.todayir.com</u> 及香港交易所披露易網站 <u>www.hkexnews.hk</u>,歡迎瀏覽。請在 本 公 司 網 站 , 或在香港交易所披露易網站瀏覽有關文件。

如 欲 選 擇 有 別 於 閣 下 所 選 擇 的 本 公 司 公 司 通 訊 之 語 言 版 本 或 收 取 方 式 , 請 以 書 面 或 以 電 郵 方 式 $\frac{1}{1}$ $\frac{1}{1}$

如 閣下對本信函內容有任何疑問,請致電本公司電話查詢熱線(852) 2862 8688,辦公時間為星期一至五(公眾假期除外)上午 9 時正至下午 6 時正。

代表國藥控股股份有限公司

董事長

于清明

謹啟

2023年8月30日

- * 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。
- 附註1:本信函收件對象為本公司登記H股股東。該等人士的姓名載列於H股股東名冊上。如果 閣下已出售或轉讓全部所持有的本公司H股股份,則無需要理會本信函及其背面的 申請寿格。
- 附註2:本公司公司通訊(「公司通訊」)指本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件,其中包括但不限於:(a)年度報告及財務摘要報告(如適用);(b) 中期報告及中期摘要報告(如適用);(c)會議通告;(d)上市文件;(e)通函;及(f)委任代表表格。

CCS5972

Request Form 申請表格 Sinopharm Group Co. Ltd.* (the "Company") 致: To: 國藥控股股份有限公司(「本公司」) (Stock Code: 01099) (股份代號:01099) c/o Computershare Hong Kong Investor Services Limited 經香港中央證券登記有限公司 (the "H Share Registrar") (「H 股登記處」) 17M Floor, Hopewell Centre, 香港灣仔皇后大道東 183 號 183 Queen's Road East, 合和中心 17M 樓 Wanchai, Hong Kong I/We would like to receive the **CURRENT** Corporate Communication of the Company in the manner as indicated below: 本人/我們現在希望以下列方式收取本公司本次公司通訊: (Please mark **ONLY ONE** (**X**) of the following boxes) (請從下列選擇中,僅在其中**一個空格**內劃上「X」號) to receive the printed copy of the Current Corporate Communication in both English and Chinese versions; OR 收取本次公司通訊之中、英文印刷本;或 to receive the printed copy of the Current Corporate Communication in English version only; OR 僅收取本次公司通訊之英文印刷本;或 to receive the printed copy of the Current Corporate Communication in Chinese version only. 僅收取本次公司通訊之中文印刷本。 Name(s) of Registered H Share Shareholder(s)# Signature 登記 H 股股東姓名# 簽名 (Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

日期 #You are required to fill in the details if you download this Request Form from the Company's Website. 假如你從本公司網站下載本申請表格,請必須填上有關資料

Notes Mit

Address[‡] 地址#

聯絡電話號碼

閣下清楚填妥所有資料

Contact telephone number

面 用度数数用分离码 If your H shares are held in joint names, the registered H share shareholder whose name stands first on the H share register of members of the Company in respect of the joint holding should sign this Request Form in order for it to be valid. 如屬聯名登記 H 股股東,則本申請表格須由該名於本公司 H 股股東名冊上就聯名持有股份其姓名位列首位的登記 H 股股東簽署,方為有效。

Date

- Any form with more than one box marked (X), with no box marked (X), with no signature or otherwise incorrectly completed shall be void 如在本表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確,則本表格將會作廢。
- The above instruction will apply to the <u>CURRENT</u> Corporate Communication of the Company to be sent to you until you notify the Company c/o the H Share Registrar, Computershare Hong Kong Investor Services Limited, to the contrary or unless you have at anytime ceased to have any shareholding in the Company.

 上述指示適用於本公司<u>本文</u>發送予 閣下之公司通訊,直至 閣下通知本公司經H股登記處香港中央證券登記有限公司另外之安排或 閣下在任何時候停止持有本公司的任何
- For the avoidance of doubt, we do not accept any special instructions written on this Request Form.
 為免存疑,任何寫在本申請表格上的額外指示,本公司將不予接受。
 Shareholders are entitled to change the choice of language or means of receipt of the Company's Corporate Communications at any time by reasonable notice in writing or by email to the 6. Company c/o the H Share Registrar at sinopharm.ccom@computershare.com.hk.
 股東有權隨時發出合理時間的書面通知或電郵到 sinopharm.ccom@computershare.com.hk 通過 H 股登記處予本公司,要求更改本公司公司通訊之語言版本或收取方式。

The Current Corporate Communication of the Company refers to the Circular, Notice and Form of proxy of Extraordinary General Meeting dated 30 August 2023

三年八月三十日之股東特別大會之通函、通告及代表委任表格。

*The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd." 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。

Mailing Label 郵寄標籤

本申請表格所提及之本公司本次公司通訊指日期為二零二

Computershare Hong Kong Investor Services Limited

香港中央證券登記有限公司

Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this Request Form to us.

No postage is necessary if posted in Hong Kong.

閣下寄回本申請表格時,請將郵寄標籤剪貼於信封上 如在本港投寄,閣下無需支付郵費或貼上郵票。

Get in touch with us 與我們聯繫

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

垂詢 評債 投訴 Send us an enquiry Rate our service Lodge a complaint



Contact Us 聯繫我們

www.computershare.com/hk/contact